专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07481758B2 Pharmaceutically enhanced low-energy radiosurgery 有权
标题翻译：药物强化低能放射外科手术
公开(公告)号：US07481758B2
公开(公告)日：2009-01-27
申请号：US10113511
申请日：2002-04-01
申请人： Michael Weil , Kevin N. Morris
发明人： Michael Weil , Kevin N. Morris
IPC分类号： A61N5/02
CPC分类号： A61N5/10 , A61K41/0085 , A61K49/006 , A61K49/0461 , A61N2005/1091 , A61N2005/1098
摘要： Contrast agents developed specifically for x-ray diagnostics provide dose-enhanced radiotherapy and radiosurgery. The presence of heavy elements, for example, gold or iron, from these contrast agents, even small quantities, leads to a major dose increase in target tissue when combined with in vivo calibration of the amount of contrast agent. The technique can also be used in combination with other techniques, such as focused x-rays, to achieve further enhancement of therapeutic ratio. The technique is enhanced by employing oil-based contrast agents, which will remain in the target much longer than conventional agents. Through optimization of the equipment it is possible to achieve very large ratios of dose in target to dose in healthy tissue.
摘要翻译：专为x射线诊断开发的造影剂可提供剂量增强的放射治疗和放射外科手术。来自这些造影剂的重元素（例如金或铁）甚至少量的存在导致与造影剂的量的体内校准组合时靶组织中的主要剂量增加。该技术还可以与诸如聚焦X射线的其它技术结合使用，以进一步提高治疗比。该技术通过使用油性造影剂得到增强，其将比常规药剂保留在目标中更长。通过优化设备，可以在健康组织中达到非常大的剂量比例。

2. 发明授权

US5789157A Systematic evolution of ligands by exponential enrichment: tissue selex 失效
公开(公告)号：US5789157A
公开(公告)日：1998-08-04
申请号：US434425
申请日：1995-05-03
申请人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
发明人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
IPC分类号： A61K38/00 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K7/22 , C07K14/00 , C07K14/16 , C07K14/72 , C12N9/12 , C12N15/10 , C12N15/115 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： C07H19/10 , B82Y5/00 , C07H19/06 , C07H21/00 , C12N15/1048 , C12N15/115 , C12N9/1276 , C12Q1/37 , C12Q1/6811 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/558 , G01N33/56988 , G01N33/57407 , G01N33/57426 , G01N33/68 , G01N33/76 , G01N33/80 , A61K38/00 , C12N2310/13 , C12N2310/322 , C12N2310/53 , C12Q1/6886 , C40B40/00 , F02B2075/027 , G01N2333/16 , G01N2333/163 , G01N2333/4724 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/7056 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976
摘要： This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.

3. 发明授权

US5712375A Systematic evolution of ligands by exponential enrichment: tissue selex 失效
公开(公告)号：US5712375A
公开(公告)日：1998-01-27
申请号：US434001
申请日：1995-05-03
申请人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
发明人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
IPC分类号： A61K38/00 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K7/22 , C07K14/00 , C07K14/16 , C07K14/72 , C12N9/12 , C12N15/10 , C12N15/115 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07K1/14 , C07H21/04 , C12P19/34
CPC分类号： C07H19/10 , B82Y5/00 , C07H19/06 , C07H21/00 , C07K1/22 , C12N15/1048 , C12N15/115 , C12N9/1276 , C12Q1/37 , C12Q1/6811 , G01N33/53 , G01N33/5308 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/57407 , G01N33/57426 , G01N33/68 , G01N33/76 , G01N33/80 , A61K38/00 , C12N2310/13 , C12N2310/16 , C12N2310/322 , C12N2310/53 , C12N2320/13 , C12Q1/6886 , C40B40/00 , F02B2075/027 , G01N2333/16 , G01N2333/163 , G01N2333/4724 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/7056 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976
摘要： This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.

4. 发明授权

US08709380B1 Targeting agents for enhancing radiation therapy 有权
标题翻译：用于增强放射治疗的靶向剂
公开(公告)号：US08709380B1
公开(公告)日：2014-04-29
申请号：US11671222
申请日：2007-02-05
申请人： Michael D. Weil , Kevin N. Morris , Rainer M. Malzbender
发明人： Michael D. Weil , Kevin N. Morris , Rainer M. Malzbender
IPC分类号： A61K51/00 , A61M36/14 , A61K49/04 , A61K41/00 , A61K9/00
CPC分类号： A61K49/04 , A61K41/0038 , A61K47/6929
摘要： Targeting agents are provided that have an affinity for aberrant cells and tissues. These agents are comprised of chelates, ligands, and/or particles combined with high atomic weight elements so that treatment with ionizing electromagnetic radiation (X-rays, or Gamma rays) results in a higher dose to aberrant cells and tissues than other cells and tissues of a host. The invention further provide methods to enhance the tumor to normal tissue damage ratio by concentrating agents with high atomic number elements to the site of the tumor prior to administering radiotherapy. The result is greater therapeutic efficacy with fewer side effects. These compounds also permit diagnostic uses in combination with the therapeutic use.
摘要翻译：提供了对异常细胞和组织具有亲和力的靶向剂。这些试剂由与高原子量元素结合的螯合物，配体和/或颗粒组成，使得用电离电磁辐射（X射线或γ射线）治疗导致比其他细胞和组织更高的异常细胞和组织的剂量的主机。本发明还提供了在施用放射治疗之前通过具有高原子序数元素的浓缩剂将肿瘤增强至肿瘤部位的方法。结果是治疗效果更好，副作用较少。这些化合物还可以与治疗用途结合使用诊断用途。

5. 发明授权

US6114120A Systematic evolution of ligands by exponential enrichment: tissue selex 失效
标题翻译：配体通过指数富集的系统演化：组织切除
公开(公告)号：US6114120A
公开(公告)日：2000-09-05
申请号：US945909
申请日：1997-10-28
申请人： Kirk B Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
发明人： Kirk B Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
IPC分类号： C12N15/10 , C12Q1/68 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： A61K47/48092 , A61K47/48076 , C12N15/1048 , C12Q1/6811 , G01N2333/96433
摘要： A new class of nucleic acid compounds, referred to as nucleic acid ligands, have been shown to exist that have a specific binding affinity for three dimensional molecular targets, including cell surface macromolecules. The nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched and the high affinity nucleic acids are amplified for further partitioning. The high affinity nucleic acid ligands are useful in capturing target cells.
摘要翻译： PCT No.PCT / US96 / 06060 Sec。 371日期1997年10月28日第 102（e）日期1997年10月28日PCT提交1996年5月1日PCT公布。公开号WO96 / 34875 日期1996年11月7日已经显示存在一类新的核酸化合物，称为核酸配体，其对三维分子靶标（包括细胞表面大分子）具有特异性结合亲和力。核酸配体通过本发明的方法鉴定，称为通过扩增富集（SELEX）的配体的系统演化，其中核酸的候选混合物被迭代地富集，并且高亲和力核酸被扩增用于进一步分配。高亲和力核酸配体可用于捕获靶细胞。

6. 发明授权

US5864026A Systematic evolution of ligands by exponential enrichment: tissue selex 失效
标题翻译：配体通过指数富集的系统演化：组织切除
公开(公告)号：US5864026A
公开(公告)日：1999-01-26
申请号：US437667
申请日：1995-05-03
申请人： Kirk Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
发明人： Kirk Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
IPC分类号： A61K38/00 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K7/22 , C07K14/00 , C07K14/16 , C07K14/72 , C12N9/12 , C12N15/10 , C12N15/115 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07H21/04 , C07H21/02 , C12P19/34
CPC分类号： C07H19/10 , B82Y5/00 , C07H19/06 , C07H21/00 , C07K14/001 , C07K14/005 , C07K14/72 , C07K7/22 , C12N15/1048 , C12N15/115 , C12N9/1276 , C12Q1/6811 , A61K38/00 , C12N2310/13 , C12N2310/16 , C12N2310/322 , C12N2310/53 , C12N2320/13 , C12N2740/16222 , C40B40/00 , F02B2075/027
摘要： This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.
摘要翻译：本发明公开了复合组织靶的高亲和力寡核苷酸配体，特别是具有结合复合组织靶的能力的核酸配体以及获得这种配体的方法。组织靶包括细胞，亚细胞组分，聚集体或细胞，细胞集合和更有序结构。具体地，描述了对红细胞的核酸配体，鬼影，成胶质细胞瘤和淋巴瘤。

7. 发明授权

US5763566A Systematic evolution of ligands by exponential enrichment: tissue SELEX 失效
标题翻译：配体通过指数富集的系统演化：组织SELEX
公开(公告)号：US5763566A
公开(公告)日：1998-06-09
申请号：US433585
申请日：1995-05-03
申请人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
发明人： Kirk B. Jensen , Hang Chen , Kevin N. Morris , Andrew Stephens , Larry Gold
IPC分类号： A61K38/00 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K7/22 , C07K14/00 , C07K14/16 , C07K14/72 , C12N9/12 , C12N15/10 , C12N15/115 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07K5/00 , C07H21/02 , C12P19/34 , C07K13/00
CPC分类号： C07H19/10 , B82Y5/00 , C07H19/06 , C07H21/00 , C12N15/1048 , C12N15/115 , C12N9/1276 , C12Q1/6804 , C12Q1/6811 , C12Q1/6848 , C12Q1/6876 , C12Q1/70 , C12Q1/703 , A61K38/00 , C12N2310/13 , C12N2310/16 , C12N2310/322 , C12N2310/53 , C12N2320/13 , C40B40/00 , F02B2075/027
摘要： This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, glioblastomas, and lymphomas are described.
摘要翻译：本发明公开了复合组织靶的高亲和力寡核苷酸配体，特别是具有结合复合组织靶的能力的核酸配体以及获得这种配体的方法。组织靶包括细胞，亚细胞组分，聚集体或细胞，细胞集合和更有序结构。具体地，描述了对红细胞的核酸配体，鬼影，成胶质细胞瘤和淋巴瘤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式